TransThera Sciences (Nanjing), Inc. disclosed a repurchase of 32,500 H shares on 27 October 2026 under its ongoing buyback mandate. The transaction, executed on the Hong Kong Stock Exchange, was completed at prices ranging from HKD 8.53 to HKD 8.72 per share, with a volume-weighted average cost of HKD 8.62. Aggregate consideration totalled HKD 0.28 million.
Following the buyback, issued shares outstanding (excluding treasury shares) slipped marginally to 312.49 million, down 0.01%. Treasury shares increased to 0.86 million, bringing total issued shares—including treasury—to 313.35 million. The cumulative number of shares repurchased since the June 18 mandate now stands at 861,000, equivalent to 0.28% of the company’s issued share capital on the mandate date.
The repurchase falls within the board-approved limit of up to 31.27 million shares and triggers a 30-day moratorium, restricting new share issuance or further treasury share sales until 26 November 2026.
The filing was signed by Chairman and Chief Executive Officer Frank Wu, who confirmed compliance with Hong Kong Listing Rules and all relevant regulatory requirements.
Comments